PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
64.88%
Some net income increase while VET is negative at -132.60%. John Neff would see a short-term edge over the struggling competitor.
-4.50%
Negative yoy D&A while VET is 12.13%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
421.91%
Some yoy growth while VET is negative at -197.98%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-100.00%
Both cut yoy SBC, with VET at -25.75%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-204.55%
Both reduce yoy usage, with VET at -154.91%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
79.53%
AR growth of 79.53% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
100.00%
Inventory growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
-88.18%
Negative yoy AP while VET is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-153.49%
Both reduce yoy usage, with VET at -154.91%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-96.95%
Negative yoy while VET is 157.64%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
8.27%
Some CFO growth while VET is negative at -16.52%. John Neff would note a short-term liquidity lead over the competitor.
4.70%
Lower CapEx growth vs. VET's 16.07%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
-100.78%
Both yoy lines negative, with VET at -655.91%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
108.57%
Growth well above VET's 26.88%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
-164.61%
Both yoy lines negative, with VET at -67.56%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
56.01%
Debt repayment above 1.5x VET's 1.77%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.